Farallon Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Farallon Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-600,000	Closed	-$14.9M	–	109
2019 Q1	$14.9M	Sell	600,000 -400,000	-40%	-$10M	0.11%	78
2018 Q4	$18M	Buy	+1,000,000	New	+$20.4M	0.13%	70
2017 Q3	–	Sell	-610,000	Closed	-$57.1M	–	94
2017 Q2	$57.1M	Buy	610,000 +530,000	+663%	+$32.4M	0.59%	35
2017 Q1	$5.09M	Buy	+80,000	New	+$4.86M	0.06%	65
2014 Q4	–	Sell	-225,000	Closed	-$10.2M	–	100
2014 Q3	$10.2M	Hold	225,000	–	–	0.16%	66
2014 Q2	$9.32M	Buy	+225,000	New	+$11.6M	0.13%	72

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Farallon Capital Management's CLVS Position: Q2 2019 in Review

Farallon Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 600,000 shares — an estimated $14.9M sold.

Farallon Capital Management first reported a position in CLVS in Q2 2014 and held it in 6 quarters. The position peaked at $57.1M in Q2 2017. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

Farallon Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
Farallon Capital Management sold 600,000 Clovis Oncology, Inc. shares in Q2 2019, an estimated $14.9M.
Farallon Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 6 quarters.
Farallon Capital Management's Clovis Oncology, Inc. position peaked at $57.1M in Q2 2017.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Farallon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.